Latest Information Update: 10 Oct 2002
At a glance
- Originator Unknown
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 10 Oct 2002 Discontinued - Preclinical for Parkinson's disease in Europe (unspecified route)
- 07 Jun 2002 Preclinical trials in Parkinson's disease in Europe (unspecified route)